Chapter 5.2 How effective are current drug treatments for anxiety disorders, and how could they be improved?

Handbook of Behavioral Neuroscience

Volumn 17, Issue , 2008, Pages 395-411

  Baldwin, David S ^a,b   Garner, Matthew ^a,c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b Hampshire Partnership Trust   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

cognitive behavioural therapy; combination treatment; generalised anxiety disorder; panic disorder; pharmacotherapy; psychopharmacology; social anxiety disorder (social phobia); treatment efficacy; treatment response

Indexed keywords

EID: 65049087842     PISSN: 15697339     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1569-7339(07)00018-5     Document Type: Review

References (147)

1. Allgulander C., Mangano R., Zhang J., Dahl A.A., Lepola U., Sjodin I., and Emilien G. Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum. Psychopharmacol. 19 (2004) 387-396
2. Argyropoulos S.V., Hood S.D., Adrover M., Bell C.J., Rich A.S., Nash J.R., Rich N.C., Witchel H.J., and Nutt D.J. Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder. Biol. Psychiatry 56 (2004) 503-509
3. Attenburrow M.J., Williams C., Odontiadis J., Reed A., Powell J., Cowen P.J., and Harmer C.J. Acute administration of nutritionally sourced tryptophan increases fear recognition. Psychopharmacology 169 (2003) 104-107
4. Baldwin D.S. Sexual dysfunction associated with antidepressant drugs. Exp. Opin. Drug Safe. 3 (2004) 457-470
5. Baldwin D.S., and Ajel K. The role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatr. Dis. Treat. 3 (2007) 185-191
6. Baldwin D.S., Anderson I.M., Nutt D.J., Bandelow B., Bond A., Davidson J.R., den Boer J.A., Fineberg N.A., Knapp M., Scott J., and Wittchen H.-U. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. 19 (2005) 567-596
7. Baldwin D.S., Huusom A.K.T., and Maehlum E. Escitalopram and paroxetine in the treatment of generalised anxiety disorder. Randomised, double-blind, placebo-controlled, double-blind study. Br. J. Psychiatry 189 (2006) 264-272
8. Baldwin D.S., and Mayers A.G. Sexual side effects of antidepressant and antipsychotic drugs. Adv. Psychiatr. Treat. 9 (2003) 202-210
9. Baldwin D.S., and Polkinghorn C. Evidence-based pharmacotherapy of generalized anxiety disorder. Int. J. Neuropsychopharmacol. 8 (2005) 293-302
10. Ballard T.M., Wolley M.L., Prinssen E., Huwyler J., Porter R., and Spooren W. The effect of the mGlu5 receptor antagonist MPEP in rodent tests of anxiety and cognition: a comparison. Psychopharmacology 179 (2005) 218-229
11. Barlow D.H., Gorman J.M., Shear M.K., and Woods S.W. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA 283 (2000) 2529-2536
12. Baxter L.R., Schwartz J.M., Bergman K.S., Szuba M.P., Guze B.H., Mazziotta J.C., Alazraki A., Selin C.E., Ferng H.K., Munford P., and Phelps M.E. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch. Gen. Psychiatry 49 (1992) 681-689
13. Beck A.T., Emery G., and Greenberg R. Anxiety Disorders and Phobias: A Cognitive Perspective (1985), Basic, New York
14. Bell C., Forshall S., Adrover M., Nash J., Hood S., Argyropoulosm S., Rich A., and Nutt D.J. Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. J. Psychopharmacol. 16 (2002) 5-14
15. Bell C.J., Abrams J.K., and Nutt D.J. Tryptophan depletion and its implications for psychiatry. Br. J. Psychiatry 178 (2001) 399-405
16. Bertani A., Perna G., Migliarese G., Di Pasquale D., Cucchi M., Caldirola D., and Bellodi L. Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study. Pharmacopsychiatry 37 (2004) 206-210
17. Black D.W. Efficacy of combined pharmacotherapy and psychotherapy versus monotherapy in the treatment of anxiety disorders. CNS Spectrosc. 11 Suppl. (2006) 29-33
18. Blanco C., Raza M.S., Schneier F., and Liebowitz M.R. The evidence-based pharmacotherapy of social anxiety disorder. Int. J. Neuropsychopharmacol. 6 (2003) 427-442
19. Blomhoff S., Haug T.T., Hellstrom K., Holme I., Humble M., Madsbu H.P., and Wold J.E. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br. J. Psychiatry 179 (2001) 23-30
20. Bouton M.E., Mineka S., and Barlow D.H. A modern learning theory perspective on the etiology of panic disorder. Psychol. Rev. 108 (2001) 4-32
21. Brody A.L., Saxena S., Schwartz J.M., Stoessel P.W., Maidment K., Phelps M.E., and Baxter L.R. FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive compulsive disorder. Psychiatr. Res. 84 (1998) 1-6
22. Brody A.L., Saxena S., Silverman D.H., Alborzian S., Fairbanks L.A., Phelps. M.E., Huang S.C., Wu H.M., Maidment K., and Baxter Jr. L.R. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatr. Res. 91 (1999) 127-139
23. Butler A.C., Chapman J.E., Forman E.M., and Beck A.T. The empirical status of cognitive-behavioural therapy: a review of meta-analyses. Clin. Psychol. Rev. 26 (2006) 17-31
24. Carey P.D., Warwick J., Niehaus D.J., van der Linden G., van Heerden B.B., Harvey B.H., Seedat S., and Stein D.J. Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram. BMC Psychiatry 14 (2004) 4-30
25. Chalmers D., Lovenberg T., Grigoriadis D., Behan D.P., and De Souza E.B. Corticotropin-releasing factor receptors: from molecular biology to drug design. Trends Pharmacol. Sci. 17 (1996) 166-172
26. Charney D.S. Neuroanatomical circuits modulating fear and anxiety behaviors. Acta Psychiatr. Scand. Suppl. 417 (2003) 38-50
27. Charney D.S., Heninger G.R., and Breier A. Noradrenergic function and panic anxiety effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch. Gen. Psychiatry. 41 (1984) 751-763
28. Charney D.S., Woods S.W., and Heninger G.R. Noradrenergic function in generalized anxiety disorder: effects of yohimbine in healthy subjects and patients with generalized anxiety disorder. Psychiatry Res. 27 (1989) 173-182
29. Chamberlain S.R., Muller U., Blackwell A.D., Robbins T.W., and Sahakian B.J. Noradrenergic modulation of working memory and emotional memory in humans. Psychopharmacology 188 (2006) 397-407
30. Chen F., Larsen M.B., and Sánchez C. The S-enantiomer of R, S-citalopram increases inhibitor binding to the human serotonin transporter by an allosteric mechanism: comparison with other serotonin transporter inhibitors. Eur. Neuropsychopharmacol. 15 (2005) 193-198
31. Clark D.M., Ehlers A., McManus F., Hackmann A., Fennell M., Campbell H., Flower T., Davenport C., and Louis B. Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J. Consult. Clin. Psychol. 71 (2003) 1058-1067
32. Clark D.M., and McManus F. Information processing in social phobia. Biol. Psychiatry 51 (2002) 92-100
33. Coplan J.D., Liebowitz M.R., Gorman J.M., Fyer A.J., Dillon D.J., Campeas R.B., Davies S.O., Martinez J., and Klein D.F. Noradrenergic function in panic disorder. Effects of intravenous clonidine pretreatment on lactate induced panic. Biol. Psychiatry 31 (1992) 135-146
34. Costall B., and Naylor R.J. Anxiolytic potential of 5-HT3 antagonists. Pharmacol. Toxicol. 70 (1993) 157-162
35. Cottraux J., Note I.D., Cungi C., Legeron P., Heim F., Chneiweiss L., Bernard G., and Bouvard M. A controlled study of cognitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobia. Br. J. Psychiatry 167 (1995) 635-641
36. Dannon P.N., Iancu I., and Grunhaus L. Psychoeducation in panic disorder patients: effect of a self-information booklet in a randomized, masked-rater study. Depress. Anxiety 16 (2002) 71-76
37. Davidson J.R.T., Foa E.B., Huppert J., Keefe F.J., Franklin M.E., Compton J.S., Zhao N., Connor K.M., Lynch T.R., and Gadde K.M. Fluoxetine, comprehensive cognitive behavioral therapy (CCBT) and placebo in generalized social anxiety disorder. Arch. Gen. Psychiatry 61 (2004) 1005-1013
38. Davidson R.J., and Irwin W. The functional neuroanatomy of emotion and affective style. Trends Cogn. Sci. 3 (1999) 11-21
39. Delgado P.L., Miller H.L., Solomon R.M., Licinio J., Heninger G.R., Gelenberg A.J., and Charney D.S. Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol. Bull. 29 (1993) 389-396
40. Den Boer J.A., and Westenberg H.G. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. Int. Clin. Psychopharmacol. 3 (1988) 59-74
41. In: Dobson K.S. (Ed). Handbook of Cognitive-Behavioral Therapies. 2nd edn (2001), Guilford Press, New York
42. +-evoked [3H]-norepinephrine release from rat neocortical slices. Synapse 45 (2002) 171-190
43. Dording C.M., Mischoulon D., Petersen T.J., Kornbluh R., Gordon J., Nierenberg A.A., Rosenbaum J.E., and Fava M. The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists. Ann. Clin. Psychiatr. 14 (2002) 143-147
44. Durham R.C., and Turvey A.A. Cognitive therapy versus behaviour therapy in the treatment of chronic generalised anxiety. Behav. Res. Ther. 25 (1987) 229-234
45. Fava M., Thase M.E., and DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J. Clin. Psychiatr. 66 (2005) 85-93
46. Fineberg N.A., and Gale T.M. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int. J. Neuropsychopharmacol. 8 (2005) 107-129
47. Fink K., Dooley D.J., Meder W.P., Suman-Chauhan N., Duffy S., Clusmann H., and Gothert M. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 42 (2002) 229-236
48. Foa E.B., Franklin M.E., and Moser J. Context in the clinic: how well do cognitive-behavioural therapies and medications work in combination?. Biol. Psychiatry 52 (2002) 987-997
49. Furmark T., Tillfors M., Marteinsdottir I., Fischer H., Pissiota A., Langstrom B., and Fredrikson M. Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. Arch. Gen. Psychiatry 59 (2002) 425-433
50. Garner M., Mogg K., and Bradley B.P. Orienting and maintenance of gaze to facial expressions in social anxiety. J. Abnorm. Psychol. 115 (2006) 760-770
51. Goddard A.W., Brouette T., Almai A., Jetty P., Woods S.W., and Charney D. Early coadministration of clonazepam with sertraline for panic disorder. Arch. Gen. Psychiatry 58 (2001) 681-686
52. Goldberg M.R., Hollister A.S., and Robertson D. Influence of yohimbine on blood pressure, autonomic reflexes and plasma catecholamines in humans. Hypertension 5 (1983) 772-778
53. Gould R.A., Otto M.W., and Pollack M.H. A meta-analysis of treatment outcome for panic disorder. Clin. Psychol. Rev. 15 (1995) 819-844
54. Gould R.A., Otto M.W., and Pollack M.H. Cognitive behavioural and pharmacological treatment of generalised anxiety disorder: a preliminary meta-analysis. Behav. Ther. 28 (1997) 285-305
55. Grauer S.M., and Marquis K.L. Intracerebral administration of metabotropic glutamate receptor agonists disrupts prepulse inhibition of acoustic startle in Sprague-Dawley rats. Psychopharmacology 141 (1999) 405-412
56. 1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc. Natl. Acad. Sci. USA 99 (2002) 6370-6375
57. Grove G., Coplan J.D., and Hollander E. The neuroanatomy of 5-HT dysregulation and panic disorder. J. Neuropsychiatr. Clin. Neurosci. 9 (1997) 198-207
58. Hamilton S.P., Slager S.L., De Leon A.B., Heiman G.A., Klein D.F., Hodge S.E., Weissman M.M., Fyer A.J., and Knowles J.A. Evidence for genetic linkage between a polymorphism in the adenosine 2A receptor and panic disorder. Neuropsychopharmacology 29 (2004) 558-565
59. Harmer C.J., Bhagwagar Z., Perrett D.I., Vollm B.A., Cowen P.J., and Goodwin G.M. Acute SSRI administration affects the processing of social cues in healthy volunteers. Neuropsychopharmacology 28 (2003) 148-152
60. Harmer C.J., Perrett D.I., Cowen P.J., and Goodwin G.M. Administration of the beta-adrenoceptor blocker propranolol impairs the processing of facial expressions of sadness. Psychopharmacology 154 (2001) 383-389
61. Harmer C.J., Hill S.A., Taylor M.J., Cowen P.J., and Goodwin G.M. Toward a neuropsychological theory of antidepressant drug action: increase in positive emotional bias after potentiation of norepinephrine activity. Am. J. Psychiatry 160 (2003) 990-992
62. Harmer C.J., Mackay C.E., Reid C.B., Cowen P.J., and Goodwin G.M. Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol. Psychiatry 59 (2006) 816-820
63. Harmer C.J., Reid C.B., Ray M.K., Goodwin G.M., and Cowen P.J. 5HT(3) antagonism abolishes the emotion potentiated startle effect in humans. Psychopharmacology 186 (2006) 18-24
64. Harmer C.J., Rogers R.D., Tunbridge E., Cowen P.J., and Goodwin G.M. Tryptophan depletion decreases the recognition of fear in female volunteers. Psychopharmacology 167 (2003) 411-417
65. Harmer C.J., Shelley N.C., Cowen P.J., and Goodwin G.M. Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am. J. Psychiatry 161 (2004) 1256-1263
66. Hayward G., Goodwin G.M., Cowen P.J., and Harmer C.J. Low-dose tryptophan depletion in recovered depressed patients induces changes in cognitive processing without depressive symptoms. Biol. Psychiatry 57 (2005) 517-524
67. Hewlett W.A., Vongradov S., and Agras W.S. Clomipramine, clonazepam and clonidine treatment of obsessive-compulsive disorder. J. Clin. Psychopharmacol. 12 (1992) 420-430
68. Huang Z.L., Qu W.M., Eguchi N., Chen J.F., Schwarzschild M.A., Fredholm B.B., Urade Y., and Hayaishi O. Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine. Nat. Neurosci. 8 (2005) 858-859
69. Ipponi A., Lamberti C., Medica A., Bartolini A., and Malmberg-Aiello P. Tiagabine antinocioception in rodents depends on GABA(B) receptor activation: parallel antinocioception testing and medial thalamus GABA microdialysis. Eur. J. Pharmacol. 368 (1999) 205-211
70. Jackson H.C., and Nutt D.J. Effects of benzodiazepine receptor inverse agonists on locomotor activity and exploration in mice. Eur. J. Pharmacol. 221 (1992) 199-204
71. Karleyton C.E., Dougherty D.D., Pollack M.H., and Rauch S.L. Using neuroimaging to predict treatment response in mood and anxiety disorders. Ann. Clin. Psychiatry 18 (2006) 33-42
72. Kavoussi R. Pregabalin: from molecule to medicine. Eur. Neuropsychopharmacol. 16 Suppl. (2006) S128-S133
73. Kennedy S.H., Andersen H.F., and Lam R.W. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. Rev. Psychiatr. Neurosci. 31 (2006) 122-131
74. Korpi E.R., and Sinkkonen S.T. GABA-A receptor subtypes as targets for neuropsychiatric drug development. Pharmacol. Ther. 109 (2006) 12-32
75. Kramer M., Cutler N., Feighner J., et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281 (1998) 1640-1645
76. Kramer M.S., Winokur A., Kelsey J., Preskorn S.H., Rothschild A.J., Snavely D., Ghosh K., Ball W.A., Reines S.A., Munjack D., Apter J.T., Cunningham L., Kling M., Bari M., Getson A., and Lee Y. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 29 (2004) 385-392
77. Krystal J.H., McDougle C.J., Woods S.W., Price L.H., Heninger G.R., and Charney D.S. Dose-response relationship for oral idazoxan effects in healthy human subjects: comparison with oral yohimbine. Psychopharmacology 108 (1992) 313-319
78. Lader M., Stender K., Burger V., and Nil R. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress. Anxiety 19 (2004) 241-248
79. Lader M.H., and Bond A.J. Interaction of pharmacological and psychological treatments of anxiety. Br. J. Psychiatry 173 Suppl. (1998) 42-48
80. Lecrubier Y., Puech A.J., Azcona A., Bailey P.E., and Lataste X. A randomized double-blind placebo-controlled study of tropisetron in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology 112 (1993) 129-133
81. LeDoux J.E. The Emotional Brain (1996), Simon & Schuster, New York
82. Liebowitz M.R., Gelenberg A.J., and Munjack D. Venlafaxine extended release vs. placebo and paroxetine in social anxiety disorder. Arch. Gen. Psychiatry 62 (2005) 190-198
83. Little J.T., Ketter T.A., Kimbrell T.A., Danielson A., Benson B., Willis M.W., and Post R.M. Venlafaxine or bupropion responders but not nonresponders show baseline prefrontal and paralimbic hypometabolism compared with controls. Psychopharm. Bull. 32 (1996) 629-635
84. Longhurst J.G., Carpenter L.L., Epperson C.N., Price L.H., and McDougle C.J. Effects of catecholamine depletion with AMPT (alpha-methyl-para-tyrosine) in obsessive-compulsive disorder. Biol. Psychiatry 46 (1999) 573-576
85. Loo H., Dalery J., Macher J.P., and Payen A. Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin-agonist and selective 5HT2C receptor antagonist, in the treatment of major depressive disorders. Encephale 29 (2003) 165-171
86. Loo H., Hale A., and D'haenen H. Determination of the dose of agomelatine, a melatonergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int. Clin. Psychopharmacol. 17 (2002) 239-247
87. Malizia A.L., Cunningham V.J., Bell C.J., Liddle P.F., Jones T., and Nutt D.J. Decreased brain GABA-A -benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch. Gen. Psychiatry 55 (1998) 715-720
88. Marks I.M., Swinson R.P., Basaglu M., Kuch K., Norshirvani H., O'Sullivan G., Lelliott P.T., Kirby M., McNamee G., and Sengun S. Alprazolam and exposure alone and combined in panic disorder with agoraphobia: a controlled study in London and Toronto. Br. J. Psychiatry 162 (1993) 776-787
89. Mathews A., and MacLeod C. Cognitive vulnerability to emotional disorders. Ann. Rev. Clin. Psychol. 1 (2005) 167-195
90. Mavissakalian M., Michelson L., and Dealy R.S. Pharmacological treatment of agoraphobia: imipramine versus imipramine with programmed practice. Br. J. Psychiatry 143 (1983) 348-355
91. Mayberg H.S., Brannan S.K., Mahurin R.K., Jerabek P.A., Brickman J.S., Tekell J.L., Silva J.A., McGinnis S., Glass T.G., Martin C.C., and Fox P.T. Cingulate function in depression: a potential predictor of treatment response. Neuroreport 8 (1997) 1057-1061
92. McClure E.B., Adler A., Monk C.S., Cameron J., Smith S., Nelson E.E., Leibenluft E., Ernst M., and Pine D.S. fMRI predictors of treatment outcome in pediatric anxiety disorders. Psychopharmacology 191 (2007) 97-105
93. Mennin D.S., and Heimberg R.G. The impact of comorbid mood and personality disorders in the cognitive-behavioral treatment of panic disorder. Clin. Psychol. Rev. 20 (2000) 339-357
94. Millan M.J., Brocco M., Gobert A., and Dekeyne A. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology 77 (2005) 448-458
95. Mitte K., Noack P., Steil R., and Hautzinger M. A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. J. Clin. Psychopharmacol. 25 (2005) 141-150
96. Mogg K., Baldwin D.S., Brodrick P., and Bradley B.P. Effect of short-term SSRI treatment on cognitive bias in generalised anxiety disorder. Psychopharmacology 176 (2004) 466-470
97. Mogg K., and Bradley B. A cognitive-motivational analysis of anxiety. Behav. Res. Ther. 36 (1998) 809-848
98. Montgomery S.A. Major depressive disorders: clinical efficacy and tolerability of agomelatine, a new melatonergic agonist. Eur. Neuropsychopharmacol. 16 Suppl. (2006) S633-S638
99. Montgomery S.A., Kennedy S.H., Burrows G.D., Lejoyeux M., and Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int. Clin. Psychopharmacol. 19 (2004) 271-280
100. Munafo M.R., Hayward G., and Harmer C. Selective processing of social threat cues following acute tryptophan depletion. J. Psychopharmacol. 20 (2006) 33-39
101. Murphy F.C., Smith K.A., Cowen P.J., Robbins T.W., and Sahakian B.J. The effects of tryptophan depletion on cognitive and affective processing in healthy volunteers. Psychopharmacology 163 (2002) 42-53
102. Murphy S.E., Longhitano C., Ayres R.E., Cowen P.J., and Harmer C.J. Tryptophan supplementation induces a positive bias in the processing of emotional material in healthy female volunteers. Psychopharmacology 181 (2006) 121-130
103. Naukkarinen H., Raassina R., Penttinen J., Ahokas A., Jokinen R., Koponen H., Lepola U., Kanerva H., Lehtonen L., Pohjalainen T., Partanen A., Maki-Ikola O., Rouru J., and Deramciclane Dose-Finding Study Group. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study. Eur. Neuropsychopharmacol. 15 (2005) 617-623
104. Nemeroff C. New directions in the development of antidepressants: the interface of neurobiology and psychiatry. Hum. Psychopharmacol. Clin. Exp. 17 (2002) S13-S16
105. Nutt D.J., Glue P., Lawson C., and Wilson S. Evidence for altered benzodiazepine receptor sensitivity in panic disorder: effects of the benzodiazepine receptor antagonist flumazenil. Arch. Gen. Psychiatry 47 (1990) 917-925
106. Ochsner K.N., Ray R.D., Cooper J.C., Robertson E.R., Chopra S., Gabrieli J.D., and Gross J.J. For better or worse: neural systems supporting the cognitive down- and up-regulation of negative emotion. Neuroimage 23 (2004) 483-499
107. Oehrberg S., Christiansen P.E., Behnke K., Borup A.L., Severin B., Soegaard J., Calberg H., Judge R., Ohrstrom J.K., and Manniche P.M. Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br. J. Psychiatry 167 (1995) 374-379
108. Ohman A., and Mineka S. Fears, phobias, and preparedness: toward an evolved module of fear and fear learning. Psychol. Rev. 108 (2001) 483-522
109. Paoluzzi L., Singh A.S., Price D.K., Danesi R., Mathijssen R.H., Verweij J., Figg W.D., and Sparreboom A. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN 38. J. Clin. Pharmacol. 44 (2004) 854-860
110. Paquette V., Levesque J., Mensour B., Leroux J.M., Beaudoin G., Bourgouin P., and Beauregard M. "Change the mind and you change the brain": effects of cognitive-behavioral therapy on the neural correlates of spider phobia. Neuroimage 18 (2003) 401-409
111. Perlis R.H. Cytochrome P450 genotyping and antidepressants. Br. Med. J. 334 (2007) 759
112. Pollack M.H., Roy-Byrne P.P., Van Ameringen M., Snyder H., Brown C., Ondrasik J., and Rickels K. The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J. Clin. Psychiatry 66 (2005) 1401-1408
113. Pollack M.H., Simon N.M., Worthington J.J., Doyle A.L., Peters P., Toshkov F., and Otto M.W. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J. Psychopharmacol. 17 (2003) 276-282
114. Power K.G., Simpson M.B., Swanson V., and Wallace L.A. A controlled comparison of cognitive-behaviour therapy, diazepam, and placebo in the management of generalized anxiety disorder. J. Anxiety Disord. 4 (1990) 267-292
115. Rasmussen S.A., Goodman W.K., Woods S.W., Heninger G.R., and Charney D.S. Effects of yohimbine in obsessive-compulsive disorder. Psychopharmacology 93 (1987) 308-313
116. Reynolds G.P., Templeman L.A., and Zhang Z.J. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 29 (2005) 1021-1028
117. Rogers R.D., Lancaster M., Wakeley J., and Bhagwagar Z. Effects of beta-adrenoceptor blockade on components of human decision-making. Psychopharmacology 172 (2004) 157-164
118. Rogers R.D., Tunbridge E.M., Bhagwagar Z., Drevets W.C., Sahakian B.J., and Carter C.S. Tryptophan depletion alters the decision-making of healthy volunteers through altered processing of reward cues. Neuropsychopharmacology 28 (2003) 153-162
119. Roffman J.L., Marci C.D., Glick D.M., Dougherty D.D., and Rauch S.L. Neuroimaging and the functional neuroanatomy of psychotherapy. Psychol. Med. 35 (2005) 1385-1398
120. Rauch S.L., Shin L.M., Dougherty D.D., Alpert N.M., Fischman A.J., and Jenike M.A. Predictors of fluvoxamine response in contamination-related obsessive compulsive disorder: a PET symptom provocation study. Neuropsychopharmacology 27 (2002) 782-791
121. Rollman B.L., Belnap B.H., Mazumdar S., Houck P.R., Zhu F., Gardner W., Reynolds III C.F., Schulberg H.C., and Shear M.K. A randomized trial to improve the quality of treatment for panic and generalized anxiety disorders in primary care. Arch. Gen. Psychiatry 62 (2005) 1332-1341
122. Roses A. Genome-based pharmacogenetics and the pharmaceutical industry. Nat. Drug Discov. 1 (2002) 541-549
123. Roy-Byrne P.P., Craske M.G., Stein M.B., Sullivan G., Bystritsky A., Katon W., Golinelli D., and Sherbourne C.D. A randomized effectiveness trial of cognitive-behavioral therapy and medication for primary care panic disorder. Arch. Gen. Psychiatry 62 (2005) 290-298
124. Sánchez C. The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram. Basic Clin. Pharmacol. Toxicol. 99 (2006) 91-95
125. Saxena S., Brody A.L., Schwartz J.M., and Baxter L.R. Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. Br. J. Psychiatry 35 (1998) 26-37
126. Schwartz J.M., Stoessel P.W., Baxter L.R., Martin K.M., and Phelps M.E. Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-compulsive disorder. Arch. Gen. Psychiatry 53 (1996) 109-113
127. Silverstone P.H., and Salinas E. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J. Clin. Psychiatry 62 (2001) 523-539
128. Simpson H.B., Liebowitz M.R., Foa E.B., Kozak M.J., Schmidt A.B., Rowan V., Petkova E., Kjernisted K., Huppert J.D., Franklin M.E., Davies S.O., and Campeas R. Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder. Depress. Anxiety 19 (2004) 225-233
129. Slaap B.R., and den Boer J.A. The prediction of nonresponse to pharmacotherapy in panic disorder: a review. Depress. Anxiety 14 (2001) 112-121
130. Stahl S.M. Anticonvulsants as anxiolytics: Part 2. Pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels. J. Clin. Psychiatry 65 (2004) 460-461
131. Stahl S.M., Gergel I., and Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 64 (2003) 1322-1327
132. Stein D.J., Baldwin D.S., Dolberg O.T., Despiegel N., and Bandelow B. Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J. Clin. Psychiatry 67 (2006) 1741-1746
133. Stein M.B., Ron Norton G., Walker J.R., Chartier M.J., and Graham R. Do selective serotonin re-uptake inhibitors enhance the efficacy of very brief cognitive behavioral therapy for panic disorder? A pilot study. Psychiatry Res. 94 (2000) 191-200
134. Stout S., Owens M., and Nemeroff C. Neurokinin (1) receptor antagonists as potential antidepressants. Ann. Rev. Pharmacol. Toxicol. 41 (2001) 877-906
135. Swanson C.J., Bures K., Johnson M.P., Linden A.-M., Monn J.A., and Schoepp D.D. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat. Rev. Drug Discov. 4 (2005) 131-144
136. Taillon-Miller P., Gu Z., Li Q., Hillier L., and Kwok P.Y. Overlapping genomic sequences: a treasure-trove of single-nucleotide polymorphisms. Genome Res. 8 (1998) 748-754
137. Thomas H.V., Lewis G., Watson M., Bell T., Lyons I., Lloyd K., Weich S., and Sharp D. Computerised patient-specific guidelines for management of common mental disorders in primary care: a randomised controlled trial. Br. J. Gen. Pract. 54 (2004) 832-837
138. Trusheim M.R., Berndt E.R., and Douglas F.L. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov. 6 (2007) 287-293
139. Tyrer P.J., and Baldwin D.S. Generalised anxiety disorder. Lancet 368 (2006) 2156-2166
140. van Balkom A.J., Bakker A., Spinhoven P., Blaauw B.M., Smeenk S., and Ruesink B. A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments. J. Nerv. Ment. Dis. 185 (1997) 510-516
141. van Boeijen C.A., van Oppen P., van Balkom A.J., Visser S., Kempe P.T., Blankenstein N., and van Dyck R. Treatment of anxiety disorders in primary care practice: a randomised controlled trial. Br. J. Gen. Pract. 55 (2005) 763-769
142. Van der Linden G., van Heerden B., Warwick J., Wessels C., van Kradenburg J., Zungu-Dirwayi N., and Stein D.J. Functional brain imaging and pharmacotherapy in social phobia: single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram. Prog. Neuropsychopharmacol. Biol. Psychiatry 24 (2000) 419-438
143. Von Korff M., and Goldberg D. Improving outcomes in depression. Br. Med. J. 323 (2001) 948-949
144. Williams J.M.G., Watts F.N., MacLeod C., and Mathews A. Cognitive Psychology and Emotional Disorders (1997), Wiley, Chichester
145. Woods S.W., Nagy L.M., Koleszar A.S., Krystal J.H., Heninger G.R., and Charney D.S. Controlled trial of alprazolam supplementation during imipramine treatment of panic disorder. J. Clin. Psychopharmacol. 12 (1992) 32-38
146. Wong M.L., and Licinio J. From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Nat. Rev. Drug Discov. 3 (2004) 136-151
147. Zobel A., Nickel T., Kunzel H., Ackl N., Sonntag A., Ising M., and Holsboer F. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res. 34 (2000) 171-181